Luxturna (voretigene neparvovec-rzyl) — Coverage Criteria
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.44 alerts
Get alerted when Policy 05.02.44 changes without checking for updates manually.
Monitor payer policy activity
Policy governing medical necessity coverage for Luxturna (voretigene neparvovec-rzyl) for biallelic RPE65 mutation-associated retinal dystrophy, including required documentation, eligibility criteria, dosing limits, and billing codes for Wellmark members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Luxturna (voretigene neparvovec-rzyl)
Initial Approval Criteria
Covered when ALL of the following are met
Approval limited to one treatment course; injections per eye limited to one lifetime.
The policy excludes members with conditions or recent exposures that could increase risk or confound treatment effect. Specifically, therapy is not covered for females who are currently pregnant or breastfeeding. Use of high‑dose retinoid compounds within the prior 18 months is an exclusion: defined as >7500 retinol equivalent units per day (equivalent to >3300 IU/day). Recent intraocular surgery within 6 months is also an exclusion, as is prior RPE65 gene therapy in the intended eye. These exclusions must be absent at the time of authorization.
Members with preexisting ocular or systemic conditions that would interfere with the safety or efficacy of subretinal gene delivery are ineligible. The policy lists examples including malignancies whose treatment could affect central nervous system function (for example, orbital radiotherapy or leukemia with CNS/optic nerve involvement), retinopathy related to diabetic macular edema or sickle cell disease, and acquired or congenital immunodeficiency that increases susceptibility to opportunistic ocular infection (e.g., cytomegalovirus retinitis). Treating clinicians should document absence of these complicating conditions when requesting authorization.
Clinical references cited in the policy include early and longer‑term follow‑up studies of RPE65 gene therapy that demonstrated initial visual improvements but variable long‑term retinal outcomes. Notably, some reports describe persistence of early visual gains at 1–2 years, while other analyses observed advancing retinal degeneration continuing despite functional improvement. These findings indicate there may be limits to the durability of structural retinal preservation even when functional measures improve, and they inform expectations communicated to patients and documentation submitted for authorization.
Billing and Coding
| J3398 | Luxturna, Injection, voretigene neparvovec-rzyl, 1 billion vector genome |
Provider Actions, Prior Authorization & Documentation
Prior Authorization Required
Prior authorization is required. Luxturna (voretigene neparvovec-rzyl) must be prescribed and administered by an ophthalmic surgeon at a certified treatment center, and the member must meet age and diagnostic criteria. Approval is for one treatment course (1 injection per eye per lifetime) and, when approved, is authorized for 6 months.
- Prescriber qualification: ophthalmic surgeon at a certified treatment center
- Approval duration: 6 months (1 treatment course of 1 injection per eye per lifetime)
- Age requirement: ≥12 months and <65 years at time of administration
No Explicit Prior Authorization Procedure Specified
The provided source chunks do not include a separate, explicit prior authorization process flow (how to submit requests, timelines for decision, or payer-specific forms). Providers should not assume an internal step-by-step PA submission procedure is described in these sections and should consult the payer for submission instructions.
- No explicit PA submission instructions included in listed chunks
- Contact Blue Cross Blue Shield - Iowa for authorizaton submission portal/forms and timelines
Missing Required Diagnostic Documentation May Lead to Denial
Treatment will be denied if required diagnostic documentation is missing. Specifically, lack of confirmatory genetic testing establishing biallelic RPE65 pathogenic/likely pathogenic variants or absence of documentation demonstrating viable retinal cells may lead to denial.
- Genetic evidence required: biallelic RPE65 pathogenic or likely pathogenic variants (homozygous or trans compound heterozygous with segregation analysis if needed)
- Retinal viability evidence: optical coherence tomography and/or ophthalmoscopy showing required thickness/areas/visual field findings
- Missing phase/segregation data when two different variants are detected may require additional family testing
Required Documentation for Prior Authorization
For prior authorization, include all clinical and genetic documentation that establishes eligibility. Provide the genetic test report with variant classification and phase (trans vs cis) or segregation analysis when applicable, imaging reports (OCT/ophthalmoscopy) documenting viable retinal tissue, and a treatment plan indicating the certified treatment center and ophthalmic surgeon who will perform administration.
- Genetic testing report: laboratory report showing pathogenic/likely pathogenic RPE65 variants and zygosity; if two different variants detected, include segregation analysis to demonstrate trans configuration
- Ophthalmic imaging: OCT and/or ophthalmoscopy demonstrating posterior pole retinal thickness >100 μm OR ≥3 disc areas without atrophy OR remaining visual field within 30° of fixation (III4e or equivalent)
- Provider documentation: name and credentials of ophthalmic surgeon, certification status of treatment center, planned dosing and administration schedule
- Medication administration plan: timing of separate-eye administrations (≥6 days apart) and peri-procedural corticosteroid regimen
Step Therapy/Fail-First Not Specified
No step therapy requirements are specified in these chunks. Coverage is tied to meeting labeled indications and the approval criteria described (genetic, retinal viability, age, contraindications).
- No prior authorization step-therapy sequence or prerequisite therapies listed
- Coverage determination based on meeting all approval criteria rather than trials of alternate therapies
Background
Biallelic RPE65 mutation‑associated retinal dystrophy encompasses inherited disorders (including Leber congenital amaurosis / early‑onset severe retinal dystrophy) caused by pathogenic variants in both copies of the RPE65 gene. The condition leads to severe, early‑onset visual impairment due to disruption of the visual cycle in the retinal pigment epithelium. Luxturna (voretigene neparvovec‑rzyl) is an AAV‑based subretinal gene replacement therapy indicated for patients with confirmed biallelic RPE65 pathogenic or likely pathogenic variants and evidence of viable retinal cells on ophthalmic assessment. Treatment is intended to restore the retinoid cycle and improve functional vision; eligibility requires genetic confirmation and retinal structural/functional criteria as specified in the policy.
Definitions and Variant Classification
Policy History & References
Policy reviewed (next review listed: October 2025).
Policy revised in February 2020 (metadata lists a revision in Feb 2020).
Current effective date established as April 2, 2020 for Policy #05.02.44.
Next review date listed as October 2025 for Policy #05.02.44.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.